Johnson & Johnson: all 3,718 studies

Page 31 of 38. Open to participants first (155), then studies with results posted, then the rest; newest registration first within each.

• TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy VolunteerCompletedNCT00828529Phase 1
• Evaluation of Bacteria in the Mouth and Throat of Healthy Adults Before and After the Administration of Either Levofloxacin or Azithromycin, Both Antibiotic MedicationsCompletedNCT00821782Phase 1
• Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaCompletedNCT00821600Phase 1
• Ivermectin in the Treatment of Head LiceCompletedNCT00819520Phase 3
• An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart FailureCompletedNCT00813202Phase 3
• TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet FormulationCompletedNCT00812292Phase 1
• Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast ImplantApproved for marketingNCT00811525
• A Comparison of Three Medications to Treat Diarrhea in Adults.CompletedNCT00807326Phase 4
• Loperamide Grapefruit Juice Interaction PK TrialCompletedNCT00806299Phase 1
• A Randomized, Double-Blind, Parallel-Arm, Placebo and Active Controlled Dose-Ranging Study of the Efficacy and Safety of Multiple Doses of Tapentadol IR for Postoperative Pain Following Bunionectomy SurgeryCompletedNCT00806247Phase 2
• A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma PatientsNo longer availableNCT00799539
• Study on Impact of Fentanyl Matrix on Improvement of Pain and Functioning in Spinal Disorder-related PainCompletedNCT00797017
• A Dose-proportionality Study of Five Tablet Strengths of ER OROS PaliperidoneCompletedNCT00796835Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796640Phase 1
• A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release FormulationsCompletedNCT00796471Phase 1
• A Study of Dopamine Type 2 (D2) Receptor Occupancy Following a Single Oral Dose of OROS PaliperidoneCompletedNCT00796432Phase 1
• A Study of Paliperidone Enantiomer Disposition With Different Formulations and the Bioavailability of Immediate- and Extended-release PaliperidoneCompletedNCT00796276Phase 1
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderCompletedNCT00796081Phase 1
• A Study of Plasma Concentrations, Metabolism and Excretion of 14C-paliperidone After a Single Oral DoseCompletedNCT00796029Phase 1
• A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ERCompletedNCT00791713Phase 1
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
• A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal FunctionCompletedNCT00791401Phase 1
• A Study of QT and QTc Intervals in Patients Administered Immediate Release PaliperidoneCompletedNCT00791349Phase 1
• A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver FunctionCompletedNCT00791284Phase 1
• A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With SchizophreniaCompletedNCT00791232Phase 1
• A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IRCompletedNCT00791193Phase 1
• A Study of the Dose Proportionality of Extended Release PaliperidoneCompletedNCT00791167Phase 1
• A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleCompletedNCT00790777Phase 1
• A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00786201Phase 2
• In-Home Use Study to Evaluate Use of an Intimate Health Product in FemalesCompletedNCT00778934Not applicable
• Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).CompletedNCT00778518Phase 2
• VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.CompletedNCT00775125Phase 1
• Bioequivalence Study of Patches With Different Equilibration ProfilesCompletedNCT00775086Phase 1
• An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable RisperidoneCompletedNCT00774085
• A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)CompletedNCT00771251Phase 3
• Observational Study on the Patients With Pain MedicationsCompletedNCT00771212
• An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer PainCompletedNCT00771199Phase 4
• CARTO 3 Human Patch StudyWithdrawnNCT00767390
• TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.CompletedNCT00767117Phase 1
• An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)TerminatedNCT00766402Phase 4
• Pilot Study of a New Nicotine Replacement TherapyCompletedNCT00764439Phase 2
• PREVELLE Shape (CX002) Dermal Filler ProtocolCompletedNCT00764257Phase 3
• Study to Evaluate Diphenhydramine in Children and AdolescentsCompletedNCT00762749Phase 1
• Phenylephrine Pediatric Pharmacokinetic StudyCompletedNCT00762567Phase 1
• Diagnostic Evaluation of the Tear FilmCompletedNCT00761917
• A Study to Determine the Performance of the Press Fit Condylar (P.F.C.) Sigma RP-F Knee SystemTerminatedNCT00761410Phase 4
• Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.CompletedNCT00758030Phase 1
• An Exploratory Study of Tramadol Hydrochloride in Patients With Osteoarthritis of the Knee or Low Back PainCompletedNCT00752661Phase 2
• TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend CapsuleCompletedNCT00752648Phase 1
• Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne VulgarisCompletedNCT00752635Phase 4
• TMC435350-TiDP16-C109: A Safety Study for TMC435350 in an Oral Solution Containing Either 100, 200 or 400 mg Equivalent of TMC435350 or Placebo in Healthy Japanese Male VolunteersCompletedNCT00752544Phase 1
• A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00752518Phase 1/2
• A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or SeparatelyCompletedNCT00752466Phase 1
• 24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With SchizophreniaCompletedNCT00752427Phase 3
• TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir TabletCompletedNCT00752310Phase 1
• Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the EyebrowsCompletedNCT00752297Phase 3
• A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the EyebrowsCompletedNCT00752258Phase 3
• Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the EyebrowsCompletedNCT00752050Phase 3
• Study of the Mentor Becker Expander/Breast Implant in Subjects Who Are Undergoing Primary Breast ReconstructionTerminatedNCT00750685Phase 3
• A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, InclusiveCompletedNCT00747695Phase 1
• A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, InclusiveCompletedNCT00747526Phase 1
• Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee OsteoarthritisCompletedNCT00745069Phase 2
• TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.CompletedNCT00744887Phase 1
• TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.CompletedNCT00744809Phase 1
• TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.CompletedNCT00744770Phase 1
• Miglustat in Cystic FibrosisCompletedNCT00742092Phase 2
• Biologic Treatment Registry Across CanadaCompletedNCT00741793
• TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.TerminatedNCT00741741Phase 1
• TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.CompletedNCT00741169Phase 1
• Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic UlcersCompletedNCT00740922
• TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.CompletedNCT00740389Phase 1
• TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.CompletedNCT00739622Phase 1
• A Complicated Skin and Soft-tissue Infection Patient RegistryCompletedNCT00737269
• Long-term Clinical Effectiveness of the Delta Xtend Reverse Total ShoulderTerminatedNCT00737087Not applicable
• TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.CompletedNCT00736905Phase 1
• Long-term Study of The Press Fit Condylar (P.F.C.) Sigma Total Knee Replacement SystemTerminatedNCT00734110Phase 4
• A Study to Evaluate the DePuy Minimally Invasive Unicompartmental KneeTerminatedNCT00734084Phase 4
• Survivorship of the Press Fit Condylar (P.F.C.) Sigma Fixed Bearing Knee With a Cobalt Chrome Tibial TrayCompletedNCT00734019
• The Press Fit Condylar (P.F.C.) Sigma Metal-backed Versus All-polyCompletedNCT00733928Phase 4
• Long-term Study of the DePuy Low Contact Stress (LCS) Complete Total Knee SystemCompletedNCT00733915Phase 4
• Outcome Study of Total Knee Arthroplasty in Asian PatientsCompletedNCT00733694Phase 4
• The Press Fit Condylar (P.F.C.) Sigma Rotating Platform (RP) TC3 Revision Knee in Revision Knee ArthroplastyTerminatedNCT00733681Phase 4
• A Study to Evaluate the Performance of the DePuy Low Contact Stress (LCS®) Complete Anterior-Posterior Glide (APG) Mobile Bearing KneeTerminatedNCT00733486Phase 4
• Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of NetherlandsCompletedNCT00731536
• An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With SchizophreniaCompletedNCT00728195Phase 2
• A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT00727987Phase 3
• Post Marketing Surveillance of RemicadeCompletedNCT00724529
• Remicade Infusion Management ProgramCompletedNCT00723905
• Global® AP™ Total Shoulder ArthroplastyCompletedNCT00719771Not applicable
• Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)CompletedNCT00719498Phase 3
• Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy VolunteersCompletedNCT00714584Phase 1
• Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy VolunteersCompletedNCT00714558Phase 1
• A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM) /Ethinyl Estradiol (EE) in Healthy Women.CompletedNCT00709982Phase 1
• Bioequivalence Study of the Oral Contraceptive (OC) Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.CompletedNCT00709644Phase 1
• A Drug Interaction Study of Folic Acid and Oral Contraceptive Tablets Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) in Healthy Women.CompletedNCT00709332Phase 1
• Bioavailability Study of Folic Acid in Healthy WomenCompletedNCT00709267Phase 1
• Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.CompletedNCT00709189Phase 1
• Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and AdolescentsCompletedNCT00708084Phase 2
• A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2

← Johnson & Johnson overview and focus areas